Journals / Haseki Tıp Bülteni / 2019 / Cilt: 57 - Sayı: 3

Early Diagnosis of Fanconi-Bickel Syndrome and a Novel Mutation in SLC2A2 Gene

Erken Dönemde Tanı Alan Bir Fanconi-Bickel Sendromu Olgusu ve SLC2A2 Geninde Yeni Bir Mutasyon

Pages
328–331
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Awareness of early findings and initiation of galactose-restricted high protein diet may provide metabolic control and prevent late complications.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Fanconi-Bickel syndrome is a metabolic disease caused by mutations in SCL2A2 gene.
📊
Key Findings & Data:Hepatic and renal glycogen storage, fasting hypoglycemia, and renal tubular dysfunction are characteristics of the disease that is usually diagnosed at 6-10 months of age.
💡
Conclusion & Impact:Awareness of early findings and initiation of galactose-restricted high protein diet may provide metabolic control and prevent late complications.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Fanconi-Bickel syndrome is a metabolic disease caused by mutations in SCL2A2 gene. Hepatic and renal glycogen storage, fasting hypoglycemia, and renal tubular dysfunction are characteristics of the disease that is usually diagnosed at 6-10 months of age. Here, we present a case of Fanconi-Bickel syndrome in a patient who was diagnosed at 47 days of age with the findings of glycosuria, hyperglycemia and an elevated level of alkaline phosphatase (ALP). The diagnosis was confirmed by identification of a new mutation in SLC2A2 gene and metabolic control was provided by a galactose-restricted high protein diet. A 27-day-old female patient was admitted with glycosuria. It was observed that she did not gain enough weight, had fat cheeks and hepatomegaly. Biochemical investigations revealed transaminase and ALP elevation. Fasting plasma glucose level was normal whereas postprandial glucose level was 198 mg/ dL. Urinalysis revealed 1+ protein and 3+ glucose. In followup, hyperglycemia started to be more evident, the ALP level decreased, compensated metabolic acidosis developed and the diagnosis of Fanconi-Bickel syndrome was assumed at 47 days of age. Under nutrition and oral replacement therapies good metabolic control and weight gain could be achieved. Postprandial hyperglycemia and glycosuria are early diagnostic clues for Fanconi-Bickel syndrome. Awareness of early findings and initiation of galactose-restricted high protein diet may provide metabolic control and prevent late complications.

Özet

Fanconi-Bickel sendromu, SCL2A2 genindeki mutasyonlara ikincil görülen bir metabolik hastalıktır. Karaciğer ile böbrekte glikojen depolanması, açlık hipoglisemisi, renal tübüler disfonksiyon hastalığın karakteristik özellikleri olup olgular sıklıkla yaşamın 6-10. ayları arasında tanı alır. Bu yazıda, yaşamının 47. gününde glukozüri, hiperglisemi ve alkalen fosfataz (ALP) yüksekliği bulgularının saptanması ile Fanconi-Bickel sendromu tanısı alan olgu sunulmuştur. Tanı SLC2A2 genine ait yeni bir mutasyon ile doğrulanmış ve yüksek protein içerikli galaktozdan kısıtlı beslenme tedavisi ile metabolik kontrol sağlanmıştır. Yirmi yedi günlük kız hasta glukozürisinin saptanması nedeniyle polikliniğimize getirildi. Tartı alımı yetersiz olan hastanın yanakları dolgundu, hepatomegalisi mevcuttu. Biyokimyasal tetkiklerinde transaminaz ve belirgin ALP yüksekliği saptandı. Açlık glukozu normal sınırlarda olan hastanın tokluk glukoz değeri 198 mg/ dL ölçüldü. Tam idrar tetkikinde 1 (+) protein ve 3 (+) glukozu mevcuttu. İzleminde tokluk hiperglisemisinin belirginleştiği, fosfor değerinin azaldığı, kompanse metabolik asidozunun geliştiği görüldü ve yaşamının 47. gününde tanıya ulaşıldı. Beslenme tedavisi ve oral replasman tedavileri ile metabolik kontrolün ve tartı alımının sağlandığı gözlendi. Tokluk hiperglisemisi ve glukozüri Fanconi-Bickel sendromunun tanısının erken dönemde konulmasında ipucu görevi görmektedir. Erken tanı ve yüksek proteinli galaktozdan kısıtlı beslenmenin başlanması metabolik kontrolü sağlayarak geç komplikasyonların önlenmesinde etkili olabilir.

🔖

Cite This Article

ÇELİKBOYA, E., CANSEVER, M. Ş., ZUBARIOĞLU, T., YEŞİL, G., AKINCI, N. (2019). Early Diagnosis of Fanconi-Bickel Syndrome and a Novel Mutation in SLC2A2 Gene. Haseki Tıp Bülteni, Cilt: 57 - Sayı: 3, 328–331. https://ajindex.com/articles/193305

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Santer R, Klepper J. Disorders of Glucose Transport. In: Saudubray JM, Baumgartner MR, Walter J, editors. Inborn Metabolic Diseases: Diagnosis and Treatment 6th ed. Heidelberg: Springer-Verlag; 2016. p.180-1
  2. Fanconi G, Bickel H. [Chronic aminoaciduria (amino acid diabetes or nephrotic-glucosuric dwarfism) in glycogen storage and cystine disease]. Helv Paediatr Acta 1949;4:359- 96
  3. Manz F, Bickel H, Brodehl J, et al. Fanconi-Bickel syndrome. Pediatr Nephrol 1987;1:509-18
  4. Santer R, Schneppenheim R, Suter D, et al. Fanconi-Bickel syndrome--the original patient and his natural history, historical steps leading to the primary defect, and a review of the literature. Eur J Pediatr 1998;157:783-97
  5. Fridman E, Zeharia A, Markus-Eidlitz T, et al. Phenotypic variability in patients with fanconi-bickel syndrome with identical mutations. JIMD Rep 2015;15:95-104
  6. Seker-Yilmaz B, Kör D, Bulut FD, et al. Impaired glucose tolerance in Fancon-Bickel syndrome: Eight patients with two novel mutations. Turk J Pediatr 2017;59:434-41
  7. Bahíllo-Curieses MP, Garrote-Molpeceres R, MiñambresRodríguez M, et al. Glycosuria and hyperglycemia in the neonatal period as the first clinical sign of Fanconi-Bickel syndrome. Pediatr Diabetes 2018;19:180-3
  8. Bahíllo-Curieses MP, Garrote-Molpeceres R, MiñambresRodríguez M, et al. The Fanconi-Bickel syndrome: a case of neonatal onset. J Perinatol 2004;24:322-3
  9. Grünert SC, Schwab KO, Pohl M, et al. Fanconi-Bickel syndrome: GLUT2 mutations associated with a mild phenotype. Mol Genet Metab 2012;105:433-7